Index
IV 章 参考文献
1）小林寬伊，大久保憲，尾家重治：消毒薬．小林寬伊編集．［新版 増補版］消毒と滅菌のガイドライン．へるす出版，東京，2015；121-136．
2）石塚紀元，小林寬伊，尾家重治：消毒薬．小林寬伊編集．感染制御学．へるす出版，東京，1996；125-156．
3）Favero MS, Bond WW：Chemical disinfection of medical and surgical materials. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia：Lippin-cott Williams & Wilkins, 2001；881-917.
4）Widmer AF, Frei R：Decontamination, disinfection, and sterilization. In：Murray PR, et al ed. Manual of clinical microbiology, 7th ed. Washington DC：ASM Press 1999；138-164
5）Rutala WA：APIC Guideline for selection and use of disinfectants, 1996. Am J Infect Control 1996；24：313-342.
6）CDC：Guideline for Hand Hygiene in Health-Care Settings. MMWR 2002；51（RR-16）：1-45.
7）大久保憲訳，小林寬伊監訳．医療現場における手指衛生のためのCDCガイドライン．メディカ出版，大阪，2003．
8）Larson EL：APIC Guideline for handwashing and hand antisepsis in health care settings, 1995. Am J Infect Control 1995；23：251-269.
9）Prince HN, Prince DL：Principles of viral control and transmission. In：Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；543-571.
10）Kobayashi H, Tsuzuki M, Koshimizu K, et al.：Susceptibility of hepatitis B virus to disinfectants or heat. J Clin Microbiol 1984；20：214-216.
11）Bond WW, Favero MS, Petersen NJ, et al.：Inactivation hepatitis B virus by intermediate- to-high-level disinfectant chemicals. J Clin Microbiol 1983；18：535-538.
12）Prince DL, Prince HN, Thraenhart O, et al.：Methodological approaches to disinfection of human hepatitis B virus. J Clin Microbiol 1993；31：3296-3304.
13）Kobayashi H, Tsuzuki M, Hosobuchi K：Bactericidal effects of antiseptics and disinfectants against methicillin-resisitant Staphylococcus aureus. Infect Control Hosp Epidemiol 1989；10：562-564.
14）Bloomfield SF, Arthur M, Looney E, et al.：Comparative testing of disinfectant and antiseptic products using proposed European suspension testing methods. Lett Appl Microbiol 1991；13：233-237.
15）Kahan A, Philippon A, Paul G, et al.：Nosocomial infections by chlorhexidine solution contaminated with Pseudomonas pickettii（Biovar VA-I）. J Infect 1983；7：256-263.
16）Coyle-Gilchrist MM, Crewe P, Roberts G：Flavobacterium meningosepticum in the hospital environment. J Clin Path 1976；29：824-826.
17）Frank MJ, Schaffner W：Contaminated aqueous benzalkonium chloride. JAMA
1976；236：2418-2419.
18）Oie S, Kamiya A：Microbial contamination of antiseptic-soaked cotton balls. Biol Pharm Bull 1997；20：667-669.
19）Oie S, Kamiya A：Microbial contamination of antiseptics and disinfectants. Am J Infect Control 1996；24：389-395.
20）Nakashima AK, McCarthy MA, Martone WJ, et al.：Epidemic septic arthritis caused by Serratia marcescens and associated with a benzalkonium chloride antiseptic. J Clin Microbiol 1987；25：1014-1018.
21）Oie S, Kamiya A：Bacterial contamination of commercially available ethacridine lactate（acrinol）products. J Hosp Infect 1996；34：51-58.
22）太田伸，長井克浩，全田浩，他：各種消毒薬の殺真菌効果．病院薬学 1992；18：343-348．
23）高鳥浩介，鈴木文子，高橋淳子，他：クレゾール，フェノールの殺真菌効果．J Antibact Antifung Agents 1987；15：341-345．
24）吉田製薬株式会社．各種低級アルコール消毒剤によるウイルス不活化試験（社内資料）． 1997．
25）佐藤隆一，和田英己，滝沢真紀，他：各種アルコール系消毒薬の評価．医学と薬学2003；49：713-724．
26）Rutala WA, Cole EC, Wannamaker NS, et al.：Inactivation of Mycobacterium tuberculosis and Mycobacterium bovis by 14 hospital disinfectants. Am J Med 1991；（3B）：267S-271S.
27）青野昭夫，桑原龍児，房野研，他：各種消毒薬の抗酸菌に対する殺菌効果と血液添加がそれに及ぼす影響．基礎と臨床 1997；31：2655-2666．
28）van Klingeren B, Pullen W：Glutaraldehyde resistant mycobacteria from endoscope washers. J Hosp Infect 1993；25：147-149.
29）Wardle MD, Renninger GM：Bactericidal effect of hydrogen peroxide on spacecraft isolates. Appl Microbiol 1975；30：710-711.
30）Turner FJ：Hydrogen peroxide and other oxide disinfectants. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 3rd ed. Philadelphia：Lea & Febiger, 1983；240-250.
31）Mentel R, Schmidt J：Investigation on rhinovirus inactivation by hydrogen peroxide. Acta Virol 1973；17：351-354.
32）Martin LS, McDougal JS, Loskoski SL：Disinfection and inactivation of the human T lymphotropic virus typeⅢ/lymphadenopathy-associated virus. J Infect Dis 1985；152：400-403.
33）加藤真吾，平石佳之，富永恵子，他：プラーク法を用いた各種消毒剤によるHIV-1不活化の検討．基礎と臨床 1996；30：3615-3620．
34）Kaplan JK, Crawford DC, Durno AG, et al.：Inactivation of human immunodeficiency virus by Betadine. Infect Cont 1987；8：412-414.
35）川名林冶，北村敬，千葉峻三，他：ポビドンヨード（PVP-I）によるウイルスの不活化に関する研究．臨床とウイルス 1998；26：371-386．
36）Druce JD：Human immunodeficiency virus：disinfectant and control. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；573-584.
37）Thraenhart O, Jursch C：Measures for disinfection and control of viral hepatitis. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia：Lippin-cott Williams & Wilkins, 2001；585-615.
38）Lauzardo M, Rubin J：Mycobacterial disinfection. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；513-528.
39）Russell AD：Chemical sporicidal and sporostatic agents. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；529-541.
40）Merianos JJ：Surface-active agents. In：Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；283-320.
41）Block SS：Surface－active agents：amphoteric compounds. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 4th ed. Philadelphia：Lea & Febiger, 1991；263-273.
42）Denton GW：Chlorhexidine. In：Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；321-336.
43）Ali Y, Dolan MJ, Fendler EJ, Larson EL：Alcohols. In：Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；229-253.
44）Gottardi W：Iodine and iodine compounds. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；159-183.
45）Dychdala GR：Chlorine and Chlorine Compounds. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；135-157.
46）Goddard PA, McCue KA：Phenolic Compounds. In：Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；255-281.
47）Scott EM, Gorman SP：Glutaraldehyde. In：Block SS, ed. Disinfection, Sterilization, and Preservation, 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；361-381.
48）Block SS：Peroxygen Compounds. In：Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；185-204.
49）Rossmoore HW：Nitrogen Compounds. In：Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia：Lippin- cott Williams & Wilkins, 2001；383-413.
50）Thamlikitkul V, Trakulsomboon S, Louisirirotchanakul S, et al.：Microbial killing activity of peracetic acid. J Med Assoc Thai 2001；84：1375-1382.
51）ジョンソン・エンド・ジョンソン株式会社．ディスオーパ消毒液0.55％医薬品インタビューフォーム．2010年7月改訂．
52）吉田製薬株式会社．アクリノールの真菌に対する作用（社内資料）．1999．
53）Ito K, Kajiura T, Abe K：Effect of ethanol on antigenicity of hepatitis B virus envelope proteins. Jpn J Infect Dis 2002；55：117-121.
54）Jursch CA, Gerlich WH, Glebe D, et al：Molecular approaches to validate disinfectants against human hepatitis B virus. Med Microbiol Immunol（Berl）2002；190：189-197.
55）山口惠三，松本哲哉：グラム陽性菌．小林寬伊編集．感染制御学．へるす出版，東京， 1996；41-45．
56）Lowy FD：Staphylococcus aureus infections. N Engl J Med 1998；339：520-532.
57）山口恵三，大野章，石井良和，他：2010年に全国72施設の臨床材料から分離された12,866株の各種抗菌薬に対する感受性サーベイランス．Jpn J Antibiotics 2012；65：181-206
58）Hiramatsu K, CDC：Reduced susceptibility of Staphylococcus aureus to vancomycin -Japan, 1996. MMWR 1997；46：624-626.
59）CDC：Interim guidelines for prevention and control of staphylococcal infections associated with reduced susceptibility to vancomycin. MMWR 1997；46：626-628, 635.
60）Sievert DM, Boulton ML, Stoltmanet G, et al.：Staphylococcus aureus resistant to vancomycin – United States, 2002. MMWR 2002；51：565-567.
61）Noble WC, Virani Z, Cree RG：Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett 1992；93；195-198.
62）Brown MH, Skurray RA：Staphylococcal multidrug efflux protein QacA. J Mol Microbiol Biotechnol 2001；3：163-170.
63）Paulsen IT, Brown MB, Skurray RA：Proton-Dependent Multidrug Efflux Systems. Microbiol Rev 1996；60：575-608.
64）笹津備規：黄色ブドウ球菌の消毒剤耐性．日本細菌学雑誌 1996；51：755-765．
65）Russell AD：Introduction of biocides into clinical practice and the impact on antibiotic-resistant bacteria. J Appl Microbiol 2002；92 Suppl：121S-135S.
66）Shiraishi T, Nakagawa Y：Review of disinfectant susceptibility of bacteria isolated in hospital to commonly used disinfectants. Postgrad Med J 1993；69 Suppl 3：S70-77.
67）Noguchi N, Hase M, Kitta M, et al：Antiseptic susceptibility and distribution of antiseptic-resistance genes in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 1999；172：247-253.
68）辻明良，山崎智子，李秀華：バイオフィルム形成Staphylococcus aureusおよびPseudomonas aeruginosaに対する消毒薬の殺菌効果と作用温度による影響．環境感染1998；13：1-4．
69）CDC：Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006.
70）Ayliffe GAJ, Collins BJ, Lowbury EJL：Ward floors and other surfaces as reservoirs of hospital infection. J Hyg Camb 1967；65：515-537.
71）Oie S, Kamiya A：Survival of methicillin-resistant Staphylococcus aureus（MRSA）on naturally contaminated dry mops. J Hosp Infect 1996；34：145-149.
72）Rutala WA, Stiegel MM, Sarubbi FA, et al.：Susceptibility of antibiotic-susceptible and antibiotic-resistant hospital bacteria to disinfectants. Infect Control Hosp Epidemiol 1997；18：417-421.
73）Suller MTE, Russell AD：Antibiotic and biocide resistance in methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus. J Hosp Infect 1999；43：281-291.
74）Sehulster LM, Anderson RL：Susceptibility of glycopeptide-intermediate resistant Staphylococcus aureus（GISA）to surface disinfectants, hand washing chemicals, and a skin antiseptic. Abstract Y-3. 98th General Meeting of American Society for Microbiology, May, 1998：547.
75）Kajiura T, Wada H, Itoh K, et al.：Effect of antiseptics and disinfectants on methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin. Abstract P.9.2.9. Fourth International Conference of the Hospital Infection Society, September 1998. J Hosp Infect 1998；40（SA）：P.9.2.9.
76）尾家重治，神谷晃：メチシリン耐性黄色ブドウ球菌（MRSA）に対する温水の効果．環境感染 1993；8：11-14．
77）Payne DN, Babb JR, Bradley CR：An evaluation of the suitability of the European suspension test to reflect in vitro activity of antiseptics against clinically significant organisms. Lett Appl Microbiol 1999；28：7-12.
78）小倉憂也，小澤智子，野島康弘，他：複合型塩素系除菌・洗浄剤の各種病原微生物に対する有効性．環境感染 2015；30：391-398.
79）日本歯科医学会監修．エビデンスに基づいた一般歯科における院内感染対策実践マニュアル改訂版．永末書店，京都，2015．
80）Kloos WE, Bannerman TL：Update on clinical significance of coagulase-negative staphylococci. Clin Microbiol Rev 1994；7：117-140.
81）Schwalbe RS, Stapleton JT, Gilligan PH：Emergence of vancomycin resistance in coagulase-negative staphylococci. N Engl J Med 1987；316：927-931.
82）Biavasco F, Vignaroli C, Varaldo PE：Glycopeptide resistance in coagulase-negative staphylococci. Eur J Clin Microbiol Infect Dis 2000；19：403-417.
83）Garrett DO, Jochimsen E, Murfitt K, et al.：The emergence of decreased susceptibility to vancomycin in Staphylococcus epidermidis. Infect Control Hosp Epidemiol 1999；20：167-170.
84）谷村久美，大久保憲：血管内留置カテーテル挿入部位の皮膚消毒に関する検討．環境感
85）Maki DG, Ringer M, Alvarado CJ：Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991；338：339-343.
86）Appelbaum PC：Antimicrobial resistance in Streptococcus pneumoniae：an overview. Clin Infect Dis 1992；15：77-83.
87）紺野昌俊，生方公子，ペニシリン耐性肺炎球菌研究会：ペニシリン耐性肺炎球菌，改訂版．協和企画通信，東京，1999．
88）Murray BE：Vancomycin-Resistant Enterococcal Infections. N Engl J Med 2000；342：710-721.
89）Arthur M, Courvalin P：Genetics and mechanisms of glycopeptide resistance in enterococci. Antimicrob Agents Chemother 1993；37：1563-1571.
90）Noskin GA, Stosor V, Cooper I, et al.：Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces. Infect Control Hosp Epidemiol 1995；16：577-581
91）Anderson RL, Carr JH, Bond WW, et al.：Susceptibility of vancomycin-resistant enterococci to environmental disinfectants. Infect Control Hosp Epidemiol 1997；18：195-199
92）Kampf G, Hofer M, Wendt C：Efficacy of hand disinfectants against vancomycin-resistant enterococci in vitro. J Hosp Infect 1999；42：143-150.
93）Kajiura T, Wada H, Takahashi K, et al.：Evaluation of chemical disinfectants and antiseptics against clinical isolates enterococci according to EN1276. Abstract P.7.11 Fifth International Conference of the Hospital Infection Society, September 15-18, 2002.
94）清水正樹，荒明美奈子，前橋一紀，他：尿および糞便検体からの分離菌に対する消毒薬のin vitro有効性．薬理と治療 2003；31；429-433．
95）Bradley CR, Fraise AP：Heat and chemical resistance of enterococci. J Hosp Infect 1996；34：191-196.
96）山口惠三，舘田一博：グラム陰性菌．小林寬伊編集．感染制御学．へるす出版，東京， 1996；46-51．
97）Do AN, Ray BJ, Banerjee SN, et al.：Bloodstream infection associated with needleless device use and the importance of infection-control practices in the home health care setting. J Infect Dis 1999；179：442-448.
98）笹津備規：細菌の消毒剤耐性．中野昌康編集，医学微生物学の最先端．菜根出版，東京，1997；173-180．
99）坂上吉一：医療廃棄物としての殺菌消毒剤の環境細菌特にPseudomonas属および黄色ブドウ球菌に及ぼす影響．J Antibact Antifung Agents 1991；19：589-596．
100）Russell AD, Day MJ：Antibacterial activity of chlorhexidine. J Hosp Infect 1993；25：229-238
101）Hancock RE：Resistance mechanisms in Pseudomonas aeruginosa and other nonfermentative gram-negative bacteria. Clin Infect Dis 1998；27 Suppl 1：S93-99.
102）Bodey GP, Bolivar R, Fainstein V, et al.：Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 1983；5：279-313.
103）Quinn JP：Clinical problems posed by multi-resistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998；27 Suppl 1：S117-124.
104）Minami S, Akama M, Araki H, et al.：Imipenem and cephem resistant Pseudomonas aeruginosa carrying plasmids coding for class B beta-lactamase. J Antimicrob Chemother 1996；37：433-444.
105）Jones AM, Dodd ME, Webb AK：Burkholderia cepacia：current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 2001；17：295-301.
106）尾家重治，弘長恭三，神代昭，他：医薬品の微生物汚染と院内感染．薬局 1989；40：1315-1318．
107）Bergogne-Berezin E, Towner KJ：Acinetobacter spp. as nosocomial pathogens：microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996；9：148-165
108）Denton M, Kerr KG：Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998；11：57-80.
109）Wishart MM, Riley TV：Infection with Pseudomonas maltophilia hospital outbreak due to contaminated disinfectant. Med J Aust 1976；2：710-712.
110）Pokrywka M, Viazanko K, Medvick J, et al.：A Flavobacterium meningosepticum outbreak among intensive care patients. Am J Infect Control 1993；21：139-145.
111）Schoch PE, Cunha BA：Nosocomial Achromobacter xylosoxidans infections. Infect Control Hosp Epidemiol 1988；9：84-87.
112）Fields BS, Benson RF, Besser RE：Legionella and Legionnaires’disease：25 years of investigation. Clin Microbiol Rev 2002；15：506-526.
113）青山透，堀弘，他：24時間循環風呂のレジオネラ汚染とその感染防止対策．感染症学雑誌 1997；71：763-769．
114）塩田量子，武下公子，山本公，他：温泉浴槽内溺水後の肺炎患者から検出されたLegionella pneumophila SG3について．感染症学雑誌 1995；69：1356-1364．
115）厚生省生活衛生局長．建築物等におけるレジオネラ症防止対策について．生衛発第1679号平成11年11月26日．1999．
116）CDC：Guidelines for Preventing Health-Care-Associated Pneumonia, 2003. MMWR 2004；53（RR3）：1-36.
117）小林寬伊，都築正和：Legionella pneumophilaの紫外線，消毒剤及び熱に対する感受性について．感染症学雑誌 1986；60：949-950．
118）Pitout JD, Sanders CC, Sanders WE Jr：Antimicrobial resistance with focus on beta-lactam resistance in gram-negative bacilli. Am J Med 1997；103：51-59.
119）Kumarasamy KK, Toleman MA, Walsh TR, et al.：Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK：a molecular, biological, and epidemiological study. Lancet 2010；10：597-602.
120）厚生労働省健康局結核感染症課長．ニューデリー･メタロ-β-ラクタマーゼ1（NDM-1）産生多剤耐性菌について．事務連絡，平成22年8月18日．
121）Clarke SC, Haigh RD, Freestone PP, et al.：Enteropathogenic Escherichia coli infection：history and clinical aspects. Br J Biomed Sci 2002；59：123-127.
122）Podschun R, Ullmann U：Klebsiella spp. as nosocomial pathogens：epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev 1998；11：589-603
123）Sanders WE Jr, Sanders CC：Enterobacter spp.：pathogens poised to flourish at the turn of the century. Clin Microbiol Rev 1997；10：220-241.
124）Verweij PE, Van Belkum A, Melchers WJ, et al.：Interrepeat fingerprinting of third-generation cephalosporin-resistant Enterobacter cloacae isolated during an outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol 1995；16：25-29.
125）Hejazi A, Falkiner FR：Serratia marcescens. J Med Microbiol 1997；46：903-912.
126）Ito H, Arakawa Y, Ohsuka S, et al.：Plasmid-mediated dissemination of the metallo-beta-lactamase gene blaIMP among clinically isolated strains of Serratia marcescens. Antimicrob Agents Chemother 1995；39：824-829.
127）堺市保健福祉局保健衛生部保健所保健医療課編集．セラチアによる院内感染事例報告．2000．
128）東京都衛生局医療福祉部結核感染症課編集．東京都不明疾患調査班報告書．2000．
129）世田谷区．セラチア院内感染事故対策報告書 平成14年5月．2002．
130）Rozalski A, Sidorczyk Z, Kotelko K：Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 1997；61：65-89.
131）Lipsky BA, Hook EW 3rd, Smith AA, et al.：Citrobacter infections in humans：experience at the Seattle Veterans Administration Medical Center and a review of the literature. Rev Infect Dis 1980；2：746-760.
132）菅野治重：真菌．小林寬伊編集．感染制御学．へるす出版，東京，1996；55-57．
133）大久保憲：真菌による院内感染．内科 1992；70：625-631．
134）Pfaller MA：Nosocomial candidiasis：emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996；22 Suppl 2：S89-94.
135）Kwon-Chung KJ, Sorrell TC, Dromer F, et al.：Cryptococcosis：clinical and biological aspects. Med Mycol 2000；38 Suppl 1：205-213.
136）Bulmer GS：Twenty-five years with Cryptococcus neoformans. Mycopathologia 1990；109：111-122.
137）Rustan ME, Rubinstein HR, Siciliano C, et al.：Possibility of in-hospital infection by Cryptococcus neoformans in patient with AIDS. Rev Inst Med Trop Sao Paulo 1992；34：383-387.
138）Zuger A, Louie E, Holzman RS, et al.：Cryptococcal disease in patients with the acquired immunodeficiency syndrome – Diagnostic features and outcome of treatment. Ann Intern Med 1986；104：234-240.
139）CDC：Guidelines for Preventing Opportunistic Infections Among Hematopoietic Stem Cell Transplant Recipients,. MMWR 2000；49（RR10）：1-128.
140）矢野邦夫訳：造血幹細胞移植患者の日和見感染予防のためのCDCガイドライン．メディカ出版，東京，2001．
141）Loo VG, Bertrand C, Dixon C, et al.：Control of construction-associated nosocomial aspergillosis in an antiquated hematology unit. Infect Control Hosp Epidemiol 1996；17：360-364.
142）VandenBergh MF, Verweij PE, Voss A：Epidemiology of nosocomial fungal infections：invasive aspergillosis and the environment. Diagn Microbiol Infect Dis 1999；34：221-227.
143）Sherertz RJ, Belani A, Kramer BS：Impact of air filtration on nosocomial Aspergillus Infections. Unique risk of bone marrow transplant recipients. Am J Med 1987；83：709-718.
144）一山智：患者環境の清潔管理（リネン類を含む）．小林寬伊，吉倉廣，荒川宜親編集．エビデンスに基づいた感染制御（改訂2版）－第1集－基礎編．メヂカルフレンド社，東京， 2003；71-80．
145）Eucker J, Sezer O, Graf B, et al.：Mucormycoses. Mycoses 2001；44：253-260.
146）Martin ES, Elewski BE：Cutaneous fungal infections in the elderly. Clin Geriatr Med 2002；18：59-75.
147）Small PM, Fujiwara PI：Management of Tuberculosis in the United States. N Engl J Med 2001；345：189-200.
148）CDC：Guidelines for Preventing the Transmission of Mycobacterium tuberculosis in Health-Care Settings, 2005. MMWR 2005；54：RR17：1-141.
149）CDC, HICPAC：Guidelines for Environmental Infection Control in Health-Care Facilities. MMWR 2003；52（RR-10）.
150）倉辻忠俊，切替照雄訳，小林寬伊監訳：医療保健施設における環境感染制御のためのCDCガイドライン．メディカ出版，大阪，2004．
151）Nelson KE, Larson PA, Schraufnagel DE, et al.：Transmission of tuberculosis by fiber bronchoscopes. Am Rev Respir Dis 1983；127：97-100.
152）Leers WD：Disinfection Endoscopes：how not to transmit Mycobacterium tuberculosis by bronchoscopy. Can Med Assoc J 1980；123：275-283.
153）Southwich KL, Hoffmann K, Ferree K, et al.：Cluster of tuberculosis cases in North Carolina：Possible association with atomizer reuse. Am J Infect Control 2001；29：1-6.
154）FDA. FDA-Cleared Sterilants and High Level Disinfectants with General Claims for Processing Reusable Medical and Dental Devices, March 2015. FDA internet publication on September, 2015 at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm.
155）Phillips MS, von Reyn CF：Nosocomial infections due to nontuberculous mycobacteria. Clin Infect Dis 2001；33：1363-1374.
156）賀来満夫：ウイルス．小林寬伊編集．感染制御学．へるす出版，東京，1996；62-72．
157）永井勲：血中ウイルス感染症．小林寬伊編集．感染制御学．へるす出版，東京，1996；414-424
158）小林寬伊，大久保憲，尾家重治：対象疾患別消毒法．小林寬伊編集．［新版 増補版］消毒と滅菌のガイドライン．へるす出版，東京，2015；44-120．
159）Alfa MJ, Sitter DL：In-hospital evaluation of orthophthalaldehyde as a high level disinfectant for flexible endoscopes. J Hosp Infect 1994；26：15-26.
160）大久保憲：感染症の予防 血中ウイルスの消毒－熱消毒を含む－．Infection Control 1996；5：488-492．
161）厚生労働省．肝炎対策に関する有識者会議報告書 平成13年 3 月30日．2001．
162）Lee WM：Hepatitis B Virus Infection. N Engl J Med 1997；337：1733-1745.
163）公益財団法人ウイルス肝炎研究財団：B型肝炎について（一般的なQ&A）．平成26年7月改訂（改訂第4版）．
164）厚生労働省：血液製剤等に係る遡及調査ガイドラインQ&A（改正版）．厚生労働省医薬食品局長．血液製剤等に係る遡及調査ガイドラインの一部改正について 参考資料2.薬食発0730第3号．平成26年7月30日．2014．
165）Komiya Y, Katayama K, Yugi H, et al.：Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008；48：286-294.
166）小林寬伊，都築正和，織田敏次，他：B型肝炎ウイルスの不活性化．医器学 1980；50：524-525
167）Lauer GM, Walker BD：Hepatitis C Virus Infection. N Engl J Med 2001；345：41-52.
168）公益財団法人ウイルス肝炎研究財団：C型肝炎について（一般的なQ&A）．平成26年 7 月改訂（改訂第 8 版）．
169）Katayama K, Kumagai J, Komiya Y, et al.：Titration of hepatitis C virus in chimpanzees for determining the copy number required for transmission. Intervirology 2004；47：57-64.
170）Resnick L, Veren K, Salahuddin SZ, et al.：Stability and inactivation of HTLV-III/LAV under clinical and laboratory environments. JAMA 1986；255：1887-1891.
171）Harbison MA, Hammer SM：Inactivation of human immunodeficiency virus by Betadine products and chlorhexidine. J Acquir Immune Defic Syndr 1989；2：16-20.
172）Satter SA, Springthorpe VS：Survival and disinfectant inactivation of the human immunodeficiency virus：a critical review. Rev Infect Dis 1991；13：430-447.
173）International Labour Organization, World Health Organization：Joint ILO/WHO guidelines on health services and HIV/AIDS. 2005.
174）吉田美香，松岡雅雄：成人T細胞白血病／リンパ腫．日本臨床 2001；59 Suppl 7：548-556．
175）Siegel JD, HICPAC：2007 Guideline for isolation precautions：preventing transmission of infectious agents in healthcare settings, 2007.
176）矢野邦夫，向野賢治訳・編：医療現場における隔離予防策のためのCDCガイドライン．メディカ出版，大阪，2007．
177）野田伸司，渡辺実，山田不二造，他：アルコール類のウイルス不活化作用に関する研究－ウイルスに対する各種アルコールの不活化効果について．感染症学雑誌 1981；55：355-366．
178）Platt J, Bucknall RA：The disinfection of respiratory syncytial virus by isopropanol and a chlorhexidine-detergent handwash. J Hosp Infect 1985；6：89-94.
179）Mbithi JN, Springthorpe VS, Sattar SA：Chemical disinfection of hepatitis A virus on environmental surfaces. Appl Environ Microbiol 1990；56：3601-3604.
180）Doultree JC, Druce JD, Birch CJ, et al.：Inactivation of feline calicivirus, a Norwalk virus surrogate. J Hosp Infect 1999；41：51-57.
181）Chadwick PR, Beards G, Brown D, et al.：Management of hospital outbreaks of gastro-enteritis due to small round structured viruses. J Hosp Infect 2000；45：1-10.
182）清水優子，牛島廣治，北島正章，他：ヒトノロウイルスの代替としてマウスノロウイルスを用いた消毒薬による不活化効果．環境感染 2009；24：388-394.
183）Belliot G, Lavaux A, Souihel D, et al.：Use of murine norovirus as a surrogate to evaluate resistance of human norovirus to disinfectants. Appl Environ Microbiol 2008；74：3315-3318.
184）Magulski T, Paulmann D, Bischoff B, et al.：Inactivation of murine norovirus by chemical biocides on stainless steel. BMC Infect Dis 2009；9：107.
185）Abad FX, Pinto RM, Bosch A：Disinfection of human enteric viruses on fomites. FEMS Microbiol Lett 1997；156：107-111.
186）Sattar SA, Raphael RA, Lochnan H, et al.：Rotavirus inactivation by chemical disinfectants and antiseptics used in hospitals. Can J Microbiol 1983；29：1464-1469.
187）Mbithi JN, Springthorpe VS, Sattar SA：Comparative in vivo efficiencies of hand-washing agents against hepatitis A virus（HM-175）and poliovirus type 1（Sabin）. Appl Environ Microbiol 1993；59：3463-3469.
188）Richard V, Van der Auwera P, Snoeck R, et al.：Nosocomial bacteremia caused by Bacillus species. Eur J Clin Microbiol Infect Dis 1988；7：783-785.
189）Carretto E, Barbarini D, Poletti F, et al.：Bacillus cereus fatal bacteremia and apparent association with nosocomial transmission in an intensive care unit. Scand J Infect Dis 2000；32：98-100.
190）菅野治重：嫌気性菌．小林寬伊編集．感染制御学．へるす出版，東京，1996；52-54．
191）Kelly CP, Pothoulakis C, LaMont JT：Clostridium difficile Colitis. N Engl J Med 1994；330：257-262.
192）Walsh SE, Mailard JY, Russell AD：Ortho-phthalaldehyde：a possible alternative to glutaraldehyde for high level disinfection. J Applied Microbiology 1999；84：1039-1046.
193）Kaatz GW, Gitlin SD, Schaberg DR：Acquisition of Clostridium difficile from the hospital environment. Am J Epidemiol 1988；127：1289-1294.
194）Johnson RT, Gibbs CJ：Creutzfeldt-Jakob Disease and Related Transmissible Spongiform Encephalopathies. N Engl J Med 1998；339：1994-2004.
195）Cousens SN, Zeidler M, Esmonde TF, et al.：Sporadic Creutzfeldt-Jakob disease in the United Kingdom：analysis of epidemiological surveillance data for 1970-96. BMJ 1997；315：389-395.
196）Bernoulli C, Siegfried J, Baumgartner G, et al.：Danger of accidental person-to-person transmission of Creutzfeldt-Jakob disease by surgery. Lancet 1977；1：478-479.
197）Rutala WA, Weber DJ：Guideline for disinfection and sterilization of prion-contaminated medical instruments. Infect Control Hosp Epidemiol 2010；31；107-117.
198）Tateishi J, Tashima T, Kitamoto T：Practical methods for chemical inactivation of Creutzfeldt-Jakob disease pathogen. Microbiol Immunol 1991；35：163-166.
199）プリオン病及び遅発性ウイルス感染症に関する調査研究班：プリオン病感染予防ガイドライン（2008年版）．
200）World Health Organization Department of Communicable Disease Surveillance and Response. WHO Infection Control Guidelines for Transmissible Spongiform Encephalopathies：Report of a WHO Consultation. Geneva, Switzerland, 23-26 March 1999.
201）日本医師会感染症危機管理対策室・厚生省保健医療局結核感染症課監修，感染症の診断・治療研究会編集．感染症の診断・治療ガイドライン．医学書院，東京，1999．
202）日本病院薬剤師会監修，日本病院薬剤師会 感染制御専門薬剤師部門研修委員会編集．薬剤師のための感染制御マニュアル第2版．薬事日報，東京，2008；3-4．
203）吉倉廣，切替照雄：1類感染症の院内感染対策および感染症法に関わる届出等の概要．小林 伊，吉倉廣，荒川宜親編集．エビデンスに基づいた感染制御（改訂2版）－第1集－基礎編．メヂカルフレンド社，東京，2003；110-143．
204）切替照雄：2～4類感染症の院内感染対策．小林寬伊，吉倉廣，荒川宜親編集．エビデンスに基づいた感染制御－第2集－実践編．メヂカルフレンド社，東京，2003；24-39．
205）小林寬伊，大久保憲，尾家重治：感染症法とガイドライン．小林寬伊編集．［新版 増補版］消毒と滅菌のガイドライン．へるす出版，東京，2015；2-6．
206）厚生労働省健康局長：感染症の予防及び感染症の患者に対する医療に関する法律施行令の一部を改正する政令等の施行について．健発0222第2号．平成25年2月2日．
207）厚生労働省健康局長：感染症の予防及び感染症の患者に対する医療に関する法律施行規則の一部を改正する省令の施行等について．健発0307第1号．平成25年3月7日．
208）厚生労働省令第103号．平成26年9月9日．
209）平成26年法律第115号．平成26年11月21日．
210）感染症の予防及び感染症の患者に対する医療に関する法律の一部を改正する法律の施行に伴う関係政令の整備に関する政令．平成27年1月9日．
211）山西弘一，平松啓一編：標準微生物学 第8版．医学書院，東京，2002．
212）東京都新たな感染症対策委員会監修，東京都衛生局医療福祉部結核感染症課編集．東京都感染症マニュアル改訂版．2000．
213）Murray PR, Baron EJ, Pfaller MA, et al, eds. Manual of Clinical Microbiology 7th ed. Washington DC：ASM Press 1999.
214）吉田眞一，柳雄介編：戸田新細菌学，改訂32版．南山堂，東京，2002．
215）Isaacson M：Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis 2001；33：1707-1712.
216）WHO：Ebola virus disease．Fact sheet N°103. Updated August 2015.
217）Leroy EM, Kumulugui B, Pourrut X, et al.：Fruit bats as reservoirs of Ebola virus. Nature 2005；438：575-576.
218）WHO：Crimean-Congo haemorrhagic fever. Fact sheet N°208. January 2013.
219）Charrel RN, de Lamballerie X：Arenaviruses other than Lassa virus. Antiviral Res 2003；57：89-100.
220）谷英樹，福士秀悦，吉河智城，他：【Negative Strand RNA Virusのウイルス学】アレナウイルス感染症．ウイルス 2012；62：229-238．
221）Buchmeier MJ, Peters CJ, de la Torre JC.：Arenaviridae：The Virus and their Replication. In Fields Virology, 5th ed., vol. 2, 2007：1792-1827.
222）Carballal G, Videla CM, Merani MS：Epidemiology of Argentine hemorrhagic fever. Eur J Epidemiol 1988；4：259-274.
223）CDC：Bolivian Hemorrhagic Fever -El Beni Department, Bolivia, 1994. MMWR 1994；43：943-946.
224）de Manzione N, Salas RA, Paredes H, et al.：Venezuelan hemorrhagic fever：clinical and epidemiological studies of 165 cases. Clin Infect Dis 1998；26：308-313.
225）Salas R, de Manzione N, Tesh RB, et al.：Venezuelan haemorrhagic fever. Lancet 1991；338：1033-1036.
226）Lisieux T, Coimbra M, Nassar ES, et al.：New arenavirus isolated in Brazil. Lancet 1994；343：391-392.
227）WHO：Marburg haemorrhagic fever. Fact sheet. November 2012.
228）Lecompte E, Fichet-Calvet E, Daffis S, et al.：Mastomys natalensis and Lassa fever, West Africa. Emerg Infect Dis 2006；12：1971-1974.
229）Monath TP, Newhouse VF, Kemp GE, et al.：Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 1974；185：263-265.
230）APIC Bioterrorism Task Force, CDC Hospital Infections Program Bioterrorism Working Group：Bioterrorism Readiness Plan：A Template for Healthcare Facilities. 1999.
231）Breman JG, Henderson DA：Diagnosis and management of smallpox. N Engl J Med 2002；346：1300-1308.
232）Drexler JF, Grard G, Lukashev AN, et al.：Robustness against serum neutralization of a poliovirus type 1 from a lethal epidemic of poliomyelitis in the Republic of Congo in 2010. Proc Natl Acad Sci U S A. 2014；111：12889－12894.
233）厚生労働省：平成26年結核登録者情報調査年報集計結果（概況）．平成27年7月16日公開．インターネット公開資料．at http://www.mhlw.go.jp/bunya/kenkou/kekkaku-kansenshou03/14.html
234）WHO：Extensively drug-resistant tuberculosis（XDR-TB）：recommendations for prevention and control. WHO internet publication on November 10, 2006.
235）Ksiazek TG, Erdman D, Goldsmith C, et al.：A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003；348：1953-1966.
236）Tsang KW, Ho PL, Ooi GC, et al：A cluster of cases of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003：348；1977-1985.
237）Donnelly CA, Ghani AC, Leung GM, et al：Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003；361：1761-1766.
238）WHO：Consensus document on the epidemiology of severe acute respiratory syndrome（SARS）. WHO internet publication on October 17, 2003.
239）Seto WH, Tsang D, Yung RWH, et al.：Effectiveness of precautions against droplets and contact in prevention of nosocomial transmission of severe acute respiratory syndrome（SARS）. Lancet 2003；361：1519-1520.
240）Saknimit M, Inatsuki I, Sugiyama Y, et al.：Virucidal efficacy of physico-chemical treatments against coronaviruses and parvoviruses of laboratory animals. Jikken Dobutsu 1988；37：341-345.
241）Sattar SA, Springthorpe VS, Karim Y, et al.：Chemical disinfection of non-porous inanimate surfaces experimentally contaminated with four human pathogenic viruses. Epidemiol Infect 1989；102：493-505.
242）WHO：First data on stability and resistance of SARS coronavirus compiled by members of WHO laboratory network. WHO internet publication on May 16, 2003at
http://www.who.int/csr/sars/survival_2003_05_04/en/index.html
243）厚生労働省医薬局安全対策課長．原因不明の「重症急性呼吸器症候群」による院内感染防止対策の徹底について，医薬安発第0509001号，平成15年5月9日．2003．
244）WHO：Clinical management of severe acute respiratory infection when Middle East respiratory syndrome coronavirus（MERS-CoV）infection is suspected. interim guidance. Updated 2 July 2015.
245）CDC：Interim Infection Prevention and Control Recommendations for Hospitalized Patients with Middle East Respiratory Syndrome Coronavirus（MERS-CoV）. Updated June 2015.
246）日本環境感染学会：MERS感染予防のための暫定的ガイダンス．2015年6月25日版．
247）国立感染症研究所感染症疫学センター，国立国際医療研究センター病院国際感染症センター：中東呼吸器症候群（MERS）・鳥インフルエンザ（H7N9）に対する院内感染対策．2014年7月25日公開．インターネット公開資料. at
http://www.nih.go.jp/niid/ja/diseases/alphabet/mers/2186-idsc/4853-mers-h7-hi.html
248）Memish ZA, Zumla AI, Al-Hakeem RF, et al.：Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013；368：2487-2494.
249）Memish ZA, Zumla AI, Assiri A：Middle East respiratory syndrome coronavirus infections in health care workers. N Engl J Med. 2013；369：884-886.
250）Azhar EI, El-Kafrawy SA, Farraj SA, et al.：Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med. 2014；370：2499-2505.
251）Yang L, Wu Z, Ren X, et al.：MERS-related betacoronavirus in Vespertilio superans bats, China. Emerg Infect Dis 2014；20：1260-1262.
252）WHO：Middle East respiratory syndrome coronavirus. Fact sheet N°401. June 2015.
253）国立感染症研究所感染症情報センター：鳥インフルエンザ感染が疑われる患者に対する医療機関での対応．平成19年1月4日公開．インターネット公開資料． at
http://idsc.nih.go.jp/disease/avian_influenza/56idsc-hosp.html
254）WHO：Aide-Memoire-Infection control recommendations for avian influenza in health-care facilities. WHO internet publication on April 2008.
255）Gao R, Cao B, Hu Y, et al.：Human infection with a novel avian-origin influenza A （H7N9）virus. N Engl J Med 2013；368：1888-1897.
256）Lo YC, Chen WC, Huang WT, et al.：Surveillance of avian influenza A（H7N9）virus infection in humans and detection of the first imported human case in Taiwan, 3 April to 10 May 2013. Euro Surveill 2013；18.
257）To KK, Song W, Lau SY, et al：Unique reassortant of influenza A（H7N9）virus associated with severe disease emerging in Hong Kong. J Infect 2014 Jul；69：60-68.
258）William T, Thevarajah B, Lee SF, et al.：Avian Influenza（H7N9）Virus Infection in Chinese Tourist in Malaysia, 2014. Emerg Infect Dis 2015；21：142-145.
259）WHO：Human infection with avian influenza A（H7N9）virus ― Canada. Disease outbreak news. 1 February 2015.
260）Gao HN, Lu HZ, Cao B, et al.：Clinical findings in 111 cases of influenza A（H7N9） virus infection. N Engl J Med 2013；368：2277-2285.
261）国立感染症研究所感染症疫学センター：鳥インフルエンザA（H7N9）ウイルス感染症に対する院内感染対策．2013年5月17日現在．
262）DuPont HL, Hornick RB, Snyder JM, et al.：Immunity in shigellosis. Ⅱ. Protection induced by oral live vaccine or primary infection. J Infect Dis 1972；125：12-16.
263）Keene We, McAnulty JM, Hoesly FC, et al.：A swimming-associated outbreak of hemorrhagic colitis caused by Escherichia coli O157：H7 and Shigella sonnei. N Eng J Med 1994；331：579-584.
264）Mead PS, Griffin PM：Escherichia coli O157：H7. Lancet 1998；352：1207-1212.
265）Oie S, Kamiya A, Tomita M, et al.：Efficacy of disinfectants and heat against Escherichia coli O157：H7. Microbios 1999；98：7-14.
266）Hornick RB, Greisman SE, Woodward TE, et al.：Typhoid fever：pathogenesis and immunologic control. N Engl J Med 1970；283：686-691.
267）Skidmore S：Overview of Hepatitis E Virus. Curr Infect Dis Rep 2002；4：118-123.
268）Nash D, Mostashari F, Fine A, et al.：The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med 2001；344：1802-1814.
269）CDC：Public Health Dispatch：Investigations of West Nile Virus Infections in Recipients of Blood Transfusions. MMWR 2002；51：973-974.
270）CDC：Intrauterine West Nile Virus Infection – New York, 2002. MMWR 2002；51：1135-1136.
271）CDC：Laboratory-Acquired West Nile Virus Infections – United States, 2002. MMWR 2002；51：1133-1135.
272）Cuthbert JA：Hepatitis A：old and new. Clin Microbiol Rev 2001；14：38-58.
273）Goodman RA, Carder CC, Allen JR, et al.：Nosocomial hepatitis A transmission by an adult patient with diarrhea. Am J Med 1982；73：220-226.
274）Charrel RN, Attoui H, Butenko AM, et al.：Tick-borne virus diseases of human interest in Europe. Clin Microbiol Infect 2004；10：1040-1055.
275）Ruzek D, Yakimenko VV, Karan LS, et al.：Omsk haemorrhagic fever. Lancet 2010；376：2104-2113.
276）Pattnaik P：Kyasanur forest disease：an epidemiological view in India. Rev Med Virol 2006；16：151-165.
277）Weber DJ, Rutala WA：Risks and prevention of nosocomial transmission of rare zoonotic diseases. Clin Infect Dis 2001；32：446-456.
278）Heymann DL, Szczeniowski M, Esteves K：Re-emergence of monkeypox in Africa：a review of the past six years. Br Med Bull 1998；54：693-702.
279）CDC：Multistate Outbreak of Monkeypox – Illinois, Indiana, and Wisconsin, 2003. MMWR 2003；52：537-540.
280）CDC：Updated Interim Infection Control and Exposure Management Guidance in the Health-Care and Community Setting for Patients with Possible Monkeypox Virus Infection. Internet publication on July 18, 2003.
281）WHO：Ｚika virus. Fact sheet. Updated February 2016.
282）厚生労働省健康局結核感染症課長．感染症の予防及び感染症の患者に対する医療に関する法律第12条第1項及び第14条第2項に基づく届出の基準等について（一部改正），健感発0212第1号，平成28年2月12日．2016．
283）厚生労働省健康局長．感染症の予防及び感染症の患者に対する医療に関する法律施行令及び検疫法施行令の一部を改正する政令及び検疫法施行規則の一部を改正する省令の施行について（施行通知），健発0205第3号，平成28年2月5日．2016．
284）Yu XJ, Liang MF, Zhang SY, et al.：Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China. N Engl J Med 2011；364：1523-1532.
285）Xu. B, Liu X L, Huang XX, et al.：Metagenomic Analysis of Fever, Thrombocytopenia and Leukopenia Syndrome（FTLS）in Henan Province, China：Discovery of a New Bunyavirus. PLoS Pathog 2011；7：e1002369.
286）Gai ZT, Zhang Y, Liang MF, et al.：Clinical progress and risk factors for death in severe fever with thrombocytopenia syndrome patients. J Infect Dis 2012；206：1095-1102.
287）Zhang YZ, Zhou DJ, Qin XC, et al.：The ecology, genetic diversity, and phylogeny of Huaiyangshan virus in China. J Virol 2012；86：2864-2868.
288）Zhongtao Gai Z, Liang M, Zhang Y, et al.：Person-to-Person Transmission of Severe Fever With Thrombocytopenia Syndrome Bunyavirus Through Blood Contact. Clin Infect Dis 2012；54：249-252.
289）Tang X, Wu W, Wang H, et al.：Human-to-human transmission of severe fever with thrombocytopenia syndrome bunyavirus through contact with infectious blood. J Infect Dis 2013；20：736-739.
290）Bao CJ, Guo XL, Qi X, et al.：A family cluster of infections by a newly recognized bunyavirus in eastern China, 2007：further evidence of person-to-person transmission. Clin Infect Dis 2011；53：1208-1214.
291）“厚生労働省健康局結核感染症課長：重症熱性血小板症候群（SFTS）の国内での発生について（情報提供及び協力依頼）健感発0130第1号平成25年1月30日.
（別添1）病原微生物検出情報（IASR）速報 国内で初めて診断された重症熱性血小板減少症候群患者
（別添2）重症熱性血小板減少症候群について
（別添3）重症熱性血小板減少症候群に関するQ&A”
292）Simmons JH, Riley LK：Hantaviruses：an overview. Comp Med 2002；52：97-110.
293）Calisher CH：Medically important arboviruses of the United States and Canada. Clin Microbiol Rev 1994；7：89-116.
294）Gunther G, Haglund M：Tick-borne encephalopathies：epidemiology, diagnosis, treatment and prevention. CNS Drugs 2005；19：1009-1032.
295）Takashima I, Morita K, Chiba M, et al.：A case of tick-borne encephalitis in Japan and isolation of the virus. J Clin Microbiol 1997；35：1943-1947.
296）Charrel RN, de Lamballerie X, Raoult D：Chikungunya Outbreaks-The Globalization of Vectorborne Disease. N Engl Med 2007；356：769-771.
297）厚生労働省健康局結核感染症課長通知：感染症の予防及び感染症の患者に対する医療に関する法律第12条第1項及び第14条第2項に基づく届出の基準等の一部改正について（健感発0114第1号），平成23年1月14日．
298）国立感染症研究所：デング熱・チクングニア熱の診療ガイドライン．2015年5月22日.
299）Bandy U, Donnelly E：Diseases of summer：EEE and Lyme disease. R I Med 1994；77：330-331.
300）Capua I, Alexander DJ：Avian influenza and human health. Acta Trop 2002；83：1-6.
301）Eurosurveillance Weekly：European Commission announces end of avian influenza outbreaks in the Netherlands, Belgium, and Germany. Eurosurveillance Weekly 2003；7：isuue 29. Eurosurveillance internet publication on july, 2003 at
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2259
302）Chua KB：Nipah virus outbreak in Malaysia. J Clin Virol 2003；26：265-275.
303）Weaver SC, Ferro C, Barrera R, et al.：Venezuelan equine encephalitis. Annu Rev Entomol 2004；49：141-174.
304）McCormack JG：Hendra and Nipah viruses：new zoonotically-acquired human pathogens. Respir Care Clin N Am 2005；11：59-66.
305）Eaton BT, Broder CC, Wang LF：Hendra and Nipah viruses：pathogenesis and therapeutics. Curr Mol Med 2005；5：805-816.
306）Hanna JN, McBride WJ, Brookes DL, et al.：Hendra virus infection in a veterinarian. Med J Aust 2006；185：562-564.
307）McColl KA, Tordo N, Aguilar Setien AA：Bat lyssavirus infections. Rev Sci Tech 2000；19：177-196.
308）Flick R, Bouloy M：Rift Valley fever virus. Curr Mol Med 2005；5：827-834.
309）WHO：Rift Valley fever. WHO revision and internet publication on May, 2010 at
http://www.who.int/mediacentre/factsheets/fs207/en/
310）CDC：Immunization of Health-Care Workers – Recommendations of the Advisory Committee on Immunization Practices（ACIP）and the Hospital Infection Control Practices Advisory Committee（HICPAC）. MMWR 1997；46（RR-18）：1-44.
311）Weber DJ, Rutala WA, Hamilton H：Prevention and control of varicella-zoster infections in healthcare facilities. Infect Control Hosp Epidemiol 1996；17：694-705.
312）Greaves WL, Orenstein WA, Stetler HC, et al.：Prevention of rubella transmission in medical facilities. JAMA 1982；248：861-864.
313）国立感染症研究所：感染症発生動向調査（IDWR）風疹発生動向調査
http://www.nih.go.jp/niid/ja/rubella-m-111/700-idsc/2131-rubella-doko.html
314）CDC：Nationwide Rubella Epidemic -Japan, 2013. MMWR 2013；62：457-462.
315）多屋馨子：風疹の流行と先天性風疹症候群．感染制御 2013；9：337-343.
316）岡部信彦：風疹と風疹ウイルス．感染と消毒 2013；20：99-104
317）CDC：Guideline for Isolation Precautions : Preventing Transmission of Infectious Agents in Healthcare Settings 2007.
318）国立感染症研究所：医療機関における風しん対策ガイドライン.
319）Biellik RJ, Clements CJ：Strategies for minimizing nosocomial measles transmission. Bull World Health Organ 1997；75：367-375.
320）Leclair JM, Freeman J, Sullivan BF, et al.：Prevention of nosocomial respiratory syncytial virus infections through compliance with glove and gown isolation precautions. N Engl J Med 1987；317：329-334.
321）Chadwick PR, Beards G, Brown D, et al.：Management of hospital outbreak of gastro-enteritis due to small round structured viruses. J Hosp Infect 2000；45；1-10.
322）Lopman BA, Adak GK, Reacher MH, et al.：Two epidemiologic patterns of Norovirus outbreaks：surveillance in England and Wales, 1992-2000. Emerg Infect Dis 2003；9：71-77
323）Rodriguez-Baez N, O’Brien R, Qiu SQ, et al：Astrovirus, adenovirus, and rotavirus in hospitalized children：prevalence and association with gastroenteritis. J Pediatr Gastroenterol 2002；35；64-68.
324）CDC：Updated norovirus outbreak management and disease prevention guidelines. MMWR 2011；60：1-16.
325）HICPAC：Guideline for the prevention and control of norovirus gastroenteritis outbreaks in healthcare settings. 2011：1-51.
326）Teunis PF, Moe CL, Liu P, et al.：Norwalk virus：how infectious is it? J Med Virol 2008；80：1468-1476.
327）清水博之：手足口病．日本臨床 2007；65：339-342.
328）IDWR：感染症の話．手足口病．2001年．インターネット公開資料． at
http://www.nih.go.jp/niid/ja/kansennohanashi/441-hfmd.html
329）細矢光亮：手足口病，ヘルパンギーナ．小児内科 2008；40：1178-1183．
330）CDC：Hand, Foot, & Mouth Disease（HFMD）. Questions and Answers. CDC internet publication last reviewed on March 14, 2011. at hhttps://www.cdc.gov/features/handfootmouthdisease/
331）Shah VA, Chong CY, Chan KP, et al.：Clinical characteristics of an outbreak of hand, foot and mouth disease in Singapore. Ann Acad Med Singapore 2003；32：381-387.
332）CDC：Hand, Foot, & Mouth Disease（HFMD）. Fast Facts. CDC internet publication last reviewed on March 14, 2011. at https://www.cdc.gov/hand-foot-mouth/about/signs-symptoms.html
333）Chan KP, Goh KT, Chong CY, et al.：Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. Emerg Infect Dis 2003；9：78-85.
334）Ho M, Chen ER, Hsu KH, et al.：An epidemic of enterovirus 71 infection in Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999；341：929-935.
335）Wharton M, Cochi SL, Hutcheson RH, et al.：Mumps transmission in hospitals. Arch Intern Med 1990；150：47-49.
336）CDC：Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices（ACIP）, 2007. MMWR 2007；56（RR-6）：1-54.
337）Tong S, Zhu X, Li Y, et al.：New world bats harbor diverse influenza A viruses. PLos Pathog 2013；9：e1003657.
338）Gottsch JD, Froggatt JW 3rd, Smith DM, et al.：Prevention and control of epidemic keratoconjunctivitis in a teaching eye institute. Ophthalmic Epidemiol 1999；6：29-39.
339）Sakaoka H, Saheki Y, Uzuki K, et al.：Two outbreaks of herpes simplex virus type 1 nosocomial infection among newborns. J Clin Microbiol 1986；24：36-40.
340）国立感染症研究所：ロタウイルス感染性胃腸炎とは.
341）World Health Organization：Rotavirus vaccines. WHO position paper－January 2013. Wkly Epidemiol Rec 2013；88：49-64.
342）CDC：Notes from the field：outbreaks of rotavirus gastroenteritis among elderly adults in two retirement communities－Illinois, 2011. MMWR 2011；60：1456.
343）Anderson EJ, Katz BZ, Polin JA, et al.：Rotavirus in adults requiring hospitalization. J Infect 2012；64：89-95.
344）千村百合，安中めぐみ，柴崎澄枝，他：日本の高齢者施設におけるA群ロタウイルス感染症の集団発生の1事例．感染症誌 2002；76：450-454.
345）山上隆也，横山宏：成人におけるA群ロタウイルスの施設内集団感染2事例の検討．感染症誌 2007；81：256-260.
346）Dennehy PH：Rotavirus infection：an update on management and prevention. Adv Pediatr 2012；59；47-74.
347）Lampe MF, Ballweber LM, Stamm WE：Susceptibility of Chlamydia trachomatis to chlorhexidine gluconate gel. Antimicrob Agents Chemother 1998；42：1726-1730.
348）Benevento WJ, Murray P, Reed CA, et al.：The sensitivity of Neisseria gonorrhoeae, Chlamydia trachomatis, and herpes simplex typeⅡto disinfection with povidone-iodine. Am J Ophthalmol 1990；109：329-333.
349）Hughes C, Maharg P, Rosario P, et al.：Possible nosocomial transmission of psittacosis. Infect Control Hosp Epidemiol 1997；18：165-168.
350）CDC：Diagnosis and management of tickborne rickettsial diseases：Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis–United States：a practical guide for physicians and other health-care and public health professionals. MMWR 2006；55 （RR-4）：1-27.
351）Lacz NL, Schwartz RA, Kapila R：Rocky Mountain spotted fever. J Eur Acad Dermatol Venereol 2006；20：411-417.
352）Buckingham SC, Marshall GS, Schutze GE, et al.：Clinical and laboratory features, hospital course, and outcome of Rocky Mountain spotted fever in children. J Pediatr 2007；150：180-184.
353）Meissner C：The effect of disinfectants on Mycoplasma pneumoniae. Z Gesamte Hyg 1977；23：404-405.
354）Lee DH, Miles RJ, Perry BF：The mycoplasmacidal properties of sodium hypochlorite. J Hyg（Lond）1985；95：243-253.
355）CDC：Laboratory-acquired human glanders–Maryland, May 2000. MMWR 2000；49：532-535
356）CDC：Glanders. CDC internet publication last reviewd on June 15, 2011 at
http://www.cdc.gov/glanders/
357）Dennis DT, Inglesby TV, Henderson DA, et al.：Tularemia as a biological weapon：medical and public health management. JAMA 2001；285：2763-2773.
358）Cheng AC, Currie BJ：Melioidosis：epidemiology, pathophysiology, and management. Clin Microbiol Rev 2005；18：383-416.
359）White NJ：Melioidosis. Lancet 2003；361：1715-1722.
360）厚生労働省健康局結核感染症課長：感染症の予防及び感染症の患者に対する医療に関する法律第12条第1項及び第14条第2項に基づく届出の基準等について（一部改正）．健感発0909第2号．平成26年9月9日.
361）Temkin E, Adler A, Lerner A, et al.：Carbapenem-resistant Enterobacteriaceae: biology, epidemiology, and management. Ann N Y Acad Sci 2014；1323：22-42.
362）CDC：Guidance for Control of Carbapenem-resistant Enterobacteriaceae（CRE）. 2012.
363）Sherertz RJ, Bassetti S, Bassetti-Wyss B：“Cloud”health-care workers. Emerg Infect Dis 2001；7：241-244.
364）厚生労働省：別紙 医師及び指定届出機関の管理者が都道府県知事に届け出る基準.
365）狩野孝之，大崎幸七，中野英二，他：重症心身障害児・者病棟で発生した百日咳集団感染についての検討．感染症学雑誌 2001；75：916-922．
366）Okamoto K, Hatakeyama S, Itoyama S, et al：Cryptococcus gattii genotype VGIIa infection in man, Japan, 2007. Emerg Infect Dis 2010；16：1155-1157.
367）Levett PN：Leptospirosis. Clin Microbiol Rev 2001；14：296-326.
368）大久保暢夫：梅毒トレポネーマおよびリン菌に対する陽性せっけんの殺菌効果について．基礎と臨床 1982；16：6181-6183．
369）吉田幸雄著．医動物学，第3版．南山堂，東京，1998．
370）PHLS：A case of hospital-acquired malaria. CDR Weekly 2002；12（8）.
371）CDC：Transfusion-Transmitted Malaria – Missouri and Pennsylvania, 1996-1998. MMWR 1999；48：253-256.
372）神谷晃，尾家重治：各種微生物に対する消毒剤の選び方．その1．細菌．消毒剤の選び方と使用上の留意点，改訂版．薬事日報社，東京，1998；51-64．
373）山本徳栄，浦辺研一，高岡正敏，他：埼玉県で発生した水道水汚染によるクリプトスポリジウム症の集団発生に関する疫学的調査．感染症学雑誌 2000；74：518-526.
374）Koch KL, Phillips DJ, Aber RC, et al.：Cryptosporidiosis in hospital personnel. Evidence for person-to-person transmission. Ann Intern Med 1985；102：593-596.
375）Wilson JA, Margolin AB：The efficacy of three common hospital liquid germicides to inactivate Cryptosporidium parvum oocysts. J Hosp Infect 1999；42：231-237.
376）Barbee SL, Weber DJ, Sobsey MD, et al.：Inactivation of Cryptosporidium parvum oocysts infectivity by disinfection and sterilization processes. Gastrointest Endosc 1999；49：605-611.
377）厚生労働省：新型インフルエンザ対策本部：基本的対処方針．2009年 5 月22日公開． at
http://www.mhlw.go.jp/kinkyu/kenkou/influenza/dl/090522-03a.pdf
378）国立感染症研究所感染症情報センター：医療機関での新型インフルエンザ対策．2009年5月20日公開，同8月25日改定．インターネット公開資料． at http://idsc.nih.go.jp/disease/swine_influenza/2009idsc/infection_control_0901.html
379）閣副第222号．平成24年4月12日．新型インフルエンザ等対策特別措置法施行令等の公布について．
380）新型インフルエンザ対策閣僚会議：新型インフルエンザ対策行動計画．平成23年9月20日公開．インターネット公開資料． at http://www.cas.go.jp/jp/seisaku/ful/kettei/110920keikaku.pdf
381）新型インフルエンザ等対策政府行動計画．平成25年6月7日．
382）新型インフルエンザ等対策ガイドライン．平成25年6月26日．
383）増田道明：NDM-1．感染と消毒 2011；18：89-93．
384）Chihara S, Okuzumi K, Yamamoto Y, et al.：First case of New Delhi metallo-beta-lactamase 1-producing Escherichia coli infection in Japan. Clin Infect Dis 2011；52：153-154
